Capsoni Simona, Giannotta Sabina, Stebel Marco, Garcia Addys Ancheta, De Rosa Roberta, Villetti Gino, Imbimbo Bruno Pietro, Pietra Claudio, Cattaneo Antonino
Lay Line Genomics S.p.A., Rome, Italy.
Am J Alzheimers Dis Other Demen. 2004 May-Jun;19(3):153-60. doi: 10.1177/153331750401900303.
Ganstigmine (CHF2819) is an acetylcholinesterase inhibitor that increases acetylcholine in rat hippocampus and ameliorates scopolamine-induced amnesia. In this article, we examined whether and how ganstigmine might prevent or rescue the neurodegenerative phenotype in AD11 antinerve growth factor (anti-NGF) mice, a transgenic model for Alzheimer's disease. The effects of ganstigmine were compared with those obtained after administration of donepezil. Results demonstrate that intraperitoneal and oral administration of ganstigmine and donepezil can reverse the cholinergic and behavioral deficit in AD11 mice but not the amyloid and phosphotau accumulation, uncovering different mechanisms leading to neurodegeneration in AD11 mice.
加兰他敏（CHF2819）是一种乙酰胆碱酯酶抑制剂，可增加大鼠海马体中的乙酰胆碱，并改善东莨菪碱诱导的失忆。在本文中，我们研究了加兰他敏是否以及如何预防或挽救AD11抗神经生长因子（anti-NGF）小鼠（一种阿尔茨海默病转基因模型）的神经退行性表型。将加兰他敏的作用与服用多奈哌齐后的作用进行了比较。结果表明，腹腔注射和口服加兰他敏及多奈哌齐可逆转AD11小鼠的胆碱能和行为缺陷，但不能逆转淀粉样蛋白和磷酸化tau蛋白的积累，揭示了AD11小鼠神经退行性变的不同机制。
